The Warrell Unit was one of the first Urogynaecology centres established in the UK remains one of the few cetre in the country that offers a single-centre location for the diagnosis and treatment of pelvic floor disorders for women; including procedures for urinary and faecal incontinence; vesicovaginal fistulas; urethral diverticulum; and major recurrent genital prolapse. The Warrell Unit was the first centre to offer minimally invasive suregery for pelvic surgery procedures. It has been at the forefront of the development of new surgical techniques through the involvement in several national multi centre surgical trials.
Our research primarily involves women who present to hospital with pelvic floor disorder. Often during the course of their visit they will be invited to participate in research.
Women wishing to volunteer should contact our research coordinator, Lucy Dwyer email@example.com
Mortality attributed to ovarian cancer (OC) exceeds that of any other gynaecological cancer, with OC being the fourth most common cause of death from cancer amongst women in the UK. Despite intensive efforts for improvement in surgery and chemotherapy there is a poor outcome for people diagnosed with OC. This is related to the fact that the majority of women are diagnosed with late stage disease (III/IV) OC and have five-year survival rate of less than 40%. Screening has the potential to pick up the disease at a much earlier stage, and therefore potentially could save thousands of lives worldwide.
The overall aim of our research is to reduce mortality and morbidity of women with ovarian cancer through the development and validation of models for risk stratification, early detection and diagnosis which incorporate clinical, epidemiological, genetic and proteomic data and to then assess how best to apply this to large populations. We are using the large biobanks resulting from clinical trials such as the United Kingdom Clinical Trial of Ovarian Cancer Screening (UKCTOCS) involving 202,000 participants in 13 collaborating UK centres and the UK Familial Ovarian Cancer Screening Study (UKFOCSS), which is investigating the effectiveness of screening women with inherited risk of ovarian cancer to:
- Develop and validate methods for predicting risk of ovarian cancer
- Develop and validate methods for earlier diagnosis of ovarian cancer
- Develop an accurate, economically and socially viable method for screening appropriate populations for ovarian cancer
Current programmes in this area include:
- PROMISE 2016 (Predicting Risk of Ovarian Malignancies, Improved Screening and Early Detection)
A research programme aimed at halving the number of deaths from ovarian cancer.
- Risk Stratification, Early Detection and Diagnosis of Ovarian Cancer
The Research programme is directed by Professor Ian Jacobs (Vice President, Dean and Head of the School of Medicine, Faculty of Medical and Human Sciences, and the Director of the Manchester Academic Health Science Centre) in collaboration with Professor Kenneth Muir, Professor Carlo Berzuini, Professor Tony Whetton and Dr Robert Graham in Manchester, Professor Usha Menon at University College London and Professor Steven Skates at Harvard Medical School.
Other gynaecological cancers
Affiliate members of the Centre lead on trials of cervical screening and have programmes to develop HPV vaccines for lower genital tract disease.